CIBC Asset Management Inc Sells 1,549 Shares of Hologic, Inc. (NASDAQ:HOLX)

CIBC Asset Management Inc lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLXFree Report) by 4.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 33,694 shares of the medical equipment provider’s stock after selling 1,549 shares during the period. CIBC Asset Management Inc’s holdings in Hologic were worth $2,407,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of HOLX. McGlone Suttner Wealth Management Inc. purchased a new position in Hologic during the fourth quarter worth about $27,000. NBC Securities Inc. purchased a new position in Hologic during the third quarter worth about $33,000. Deseret Mutual Benefit Administrators boosted its holdings in Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 155 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its stake in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 227 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 179 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $74.51 on Friday. The firm’s 50 day simple moving average is $75.67 and its 200 day simple moving average is $74.04. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $17.39 billion, a PE ratio of 38.02, a price-to-earnings-growth ratio of 2.47 and a beta of 1.00. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45.

Hologic (NASDAQ:HOLXGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. Hologic’s revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.06 EPS. As a group, analysts expect that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on HOLX. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Friday, May 3rd. Finally, Argus boosted their price target on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Read Our Latest Research Report on Hologic

Insiders Place Their Bets

In other news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Hologic Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.